secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2026-01-23T23:59:59+00:00
Accession:  0001104659-26-006267
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics receives Nasdaq bid price deficiency notice; stock at risk of delisting
--------------------------------------------------------------------------------

- Closing bid below $1.00 for 30 consecutive business days triggered Nasdaq deficiency letter.
- Company has 180 calendar days (until July 22, 2026) to regain compliance via $1.00 close for 10 consecutive days.
- If not cured by July 22, Aprea may qualify for a second 180-day period if it meets other listing standards.
- Company may consider a reverse stock split to cure the deficiency but no assurance of compliance.
- Stock continues trading on Nasdaq Capital Market under symbol APRE with no immediate delisting effect.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926006267/0001104659-26-006267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926006267/tm263963d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-006267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer